The influence of age on in vitro plasmin generation in the presence of fibrin monomer

Acta Haematologica

Volumn 115, Issue 3-4, 2006, Pages 141-151

  Parmar, Nagina ^a   Mitchell, Lesley G ^a   Berry, Leslie R ^b   Andrew, Maureen ^a   Chan, Anthony K C ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Henderson Research Center   (Canada)

Author keywords

Endothelial cells; Fibrin; Plasmin; Plasminogen

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIPLASMIN; DESAFIB; FIBRIN MONOMER; LIPOPROTEIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PLASMA; PRIORITY JOURNAL; UMBILICAL CORD; VEIN;

ADULT; AGE FACTORS; ANTIPLASMIN; BLOOD COAGULATION TESTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; INFANT, NEWBORN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 33645118694     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090927     Document Type: Article

References (55)

1. Mackinnon S, Walker ID, Davidson JF, Walker JJ: Plasma fibrinolysis during and after normal childbirth. Br J Haematol 1987;65:339-342.
2. Andrew M: Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost 1995;21:341-356.
3. Pinacho A: Paramo JA, Ezcurdia M, Rocha E: Evaluation of the fibrinolytic system in full-term neonates. Int J Clin Lab Res 1995;25: 149-152.
4. Christensen U, Sottrup-Jensen L: Mechanism of alpha 2-macroglobulin- proteinase interactions. Biochemistry 1984;23:6619-6626.
5. Wiman B, Wallen P: The specific interaction between plasminogen and fibrin. Thromb Res 1977;10:213-222.
6. Wallen P, Wiman B: Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochim Biophys Acta 1970;221:20-30.
7. Dhainaut JF, Yan SB, Cariou A, Mira JP: Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002;30:S318-S324.
8. Rezaie AR: Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001;276:15567-15570.
9. Sakamoto T, Ogawa H, Takazoe K, Yoshimura M, Shimomura H, Moriyama Y, Arai H, Okajima K: Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin. J Am Coll Cardiol 2003;42:1389-1394.
10. Wun TC, Capuano A: Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood 1987;69:1354-1362.
11. Collen D: On the regulation and control of fibrinolysis. Thromb Haemost 1980;43:77-89.
12. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-3124.
13. Marin ML, Veith FJ, Cynamon J, Sanchez LA, Lyon RT, Levine BA, Bakal CW, Suggs WD, Wengerter KR, Rivers SP: Initial experience with transluminally placed endovascular grafts for the treatment of complex vascular lesions. Ann Surg 1995;222:449-465.
14. Booth NA: Fibrinolysis and thrombosis. Baillières Best Pract Res Clin Haematol 1999;12:423-433.
15. Mosesson MW: Fibrinogen and fibrin polymerization: appraisal of the binding events. Blood Coagul Fibrinolysis 1997;8:257-267.
16. Smokovitis A: Regions of constantly increased plasminogen activator activity along the intima of the normal aorta. Haemostasis 1978;7:303-319.
17. Mishima A, Asano M, Saito T, Yamamoto S, Ukai T, Yoshitomi H, Matsumoto K, Manabe T: Pulmonary blood flow regulates plasma tissue plasminogen activator concentrations in patients with congenital heart defects. J Thorac Cardiovasc Surg 1997;113:742-747.
18. Van Hinsberg VW, Sprengers ED, Kooistra T: Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost 1987;57:148-153.
19. Reininger AJ, Heinzmann U, Reininger CB, Friedrich P, Wurzinger LJ: Flow mediated fibrin thrombus formation in an endothelium-lined model. Thromb Res 1994;74:629-641.
20. Christiansen VJ, Sims PJ, Hamilton KK: Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler Thromb Vasc Biol 1997;17: 164-171.
21. Fan Z, Larson PJ, Bognacki J, Raghunath PN, Tomaszewski JE, Kuo A, Canziani G, Chaiken I, Cines DB, Higazi AA: Tissue factor regulates plasminogen binding and activation. Blood 1998;91:1987-1998.
22. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P: Development of the human coagulation system in the full-term infant. Blood 1987;70:165-172.
23. Andrew M, Mitchell L, Berry LR, Schmidt B, Hatton MW: Fibrinogen has a rapid turnover in the healthy newborn lamb. Pediatr Res 1988;23:249-252.
24. Ries M: Molecular and functional properties of fetal plasminogen and its possible influence on clotlysis in the neonatal period. Semin Thromb Hemost 1997;23:247-252.
25. Corrigan JJ Jr, Jeter M: Histidine-rich glycoprotein and plasminogen plasma levels in term and preterm newborns. Am J Dis Child 1990;144:825-828.
26. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M: Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990;86:107-112.
27. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP: Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 1998;132:575-588.
28. Testa R, Marcovina SM: The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 1999;29:128-132.
29. Marcovina SM, Koschinsky ML: Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14:361-366.
30. Corrigan JJ Jr, Sleeth JJ, Jeter M, Lox CD: Newborn's fibrinolytic mechanism: components and plasmin generation. Am J Hematol 1989;32:273-278.
31. Ries M: Molecular and functional properties of fetal plasminogen and its possible influence on clotlysis in the neonatal period. Semin Thromb Hemost 1997;23:247-252.
32. Hilali MM, Gilliver BE: Physiological activation of plasminogen in full term newborn infants. J Clin Pathol 1984;37:1264-1267.
33. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M: Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990;86:107-112.
34. Ranson M, Andronicos NM: Plasminogen binding and cancer: promises and pitfalls. Front Biosci 2003;8:S294-S304.
35. Cheng XF, Brohlin M, Pohl G, Back O, Wallen P: Binding of tissue plasminogen activator to endothelial cells. Thromb Res 1995;77:149-164.
36. Gong Y, Kim SO, Felez J, Grella DK, Castellino FJ, Miles LA: Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J Biol Chem 2001;276:19078-19083.
37. Hajjar KA: Assembly of plasmin-generating proteins on the surface of human endothelial cells. Ann Epidemiol 1992;2:419-426.
38. Wiman B, Collen D: On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem 1979;254:9291-9297.
39. Montes R, Paramo JA, Angles-Cano E, Rocha E: Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Br J Haematol 1996;92:979-985.
40. Knofler R, Hofmann S, Weissbach G, Kuhlisch E, Neef B, Otte M, Pargac N, Nachtrodt G: Molecular markers of the endothelium, the coagulation and the fibrinolytic systems in healthy newborns. Semin Thromb Hemost 1998;24:453-461.
41. Uszynski M, Klyszejko A, Zekanowska E: Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women. Eur J Obstet Gynecol Reprod Biol 2000;93:167-171.
42. Ries M, Easton RL, Longstaff C, Zenker M, Morris HR, Dell A, Gaffney PJ: Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. Thromb Res 2002;105:247-256.
43. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L: Maturation of the hemostatic system during childhood. Blood 1992;80:1998-2005.
44. Suarez CR, Walenga J, Mangogna LC, Fareed J: Neonatal and maternal fibrinolysis: activation at time of birth. Am J Hematol 1985;19:365-372.
45. Foley ME, Clayton JK, McNicol GP: Haemostatic mechanisms in maternal, umbilical vein and umbilical artery blood at the time of delivery. Br J Obstet Gynaecol 1977;84:81-87.
46. Astedt B, Lindoff C: Plasminogen activators and plasminogen activator inhibitors in plasma of premature and term newborns. Acta Paediatr 1997;86:111-113.
47. Andrew M, Paes B, Johnston M: Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104.
48. Schneider DM, von Tempelhoff GF, Herrle B, Heilmann L: Maternal and cord blood hemostasis at delivery. J Perinat Med 1997;25:55-61.
49. Ambrus CM, Ambrus JL, Choi TS, Jung O, Mirand EA, Bartfay-Szabo A: The fibrinolysis system and its relationship to disease in the newborn. Am J Pediatr Hematol Oncol 1979;1:251-260.
50. Ekelund H, Finnstrom O: The fibrinolytic system in infants of low birth weight and-or short gestational period. Acta Paediatr Scand Suppl 1970;206(suppl):31.
51. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P: Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657.
52. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML: Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003;278:23260-23269.
53. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991;11:629-638.
54. Loscalzo J, Weinfeld M, Fless GM, Scanu AM: Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-245.
55. Hervio L, Durlach V, Girard-Globa A, Angles-Cano E: Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995;34:13353-13358.